Beta-blockers in heart failure. 2. Mode of action
2008; Wiley; Volume: 26; Issue: 1 Linguagem: Inglês
10.1111/j.1365-2710.2001.00316.x
ISSN1365-2710
AutoresSarah Nuttall, N. Langford, M. J. Kendall,
Tópico(s)Heart rate and cardiovascular health
ResumoJournal of Clinical Pharmacy and TherapeuticsVolume 26, Issue 1 p. 1-4 Beta-blockers in heart failure. 2. Mode of action S. L. Nuttall PhD, S. L. Nuttall PhD Clinical Investigation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, U.K.Search for more papers by this authorN. J. Langford MRCP, N. J. Langford MRCP Clinical Investigation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, U.K.Search for more papers by this authorM. J. Kendall MD FRCP, M. J. Kendall MD FRCP Clinical Investigation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, U.K.Search for more papers by this author S. L. Nuttall PhD, S. L. Nuttall PhD Clinical Investigation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, U.K.Search for more papers by this authorN. J. Langford MRCP, N. J. Langford MRCP Clinical Investigation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, U.K.Search for more papers by this authorM. J. Kendall MD FRCP, M. J. Kendall MD FRCP Clinical Investigation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, U.K.Search for more papers by this author First published: 07 July 2008 https://doi.org/10.1111/j.1365-2710.2001.00316.xCitations: 1 S. L. Nuttall Division of Medical Sciences, Clinical Investigation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, U.K. Tel.: +44 (0)121 4144094; fax: +44 (0)121 4141355; e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Bibliography 1 Olsson G, Wikstrand J, Warnold I, et al. (1992) Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. European Heart Journal, 13 , 28– 32. 2 Freemantle N, Cleland J, Young P, Mason J, Harrison J. (1999) β-blockade after myocardial infarction: systematic review and meta regression analysis. British Medical Journal, 318 , 1730– 1737. 3 The Norwegian Multicenter Study Group. (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine, 304 , 801– 807. 4 Beta Blocker Heart Attack Research Group. (1982) A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. Journal of the American Medical Association, 247 , 1707– 1713. 5 Australia/New Zealand Heart Failure Research Collaborative Group. (1997) Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet, 349 , 375– 380. 6 Packer M, Bristow MR, Cohn JN, et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New England Journal of Medicine, 334 , 1349– 1355. 7 CIBIS-II, Investigators and Committees. (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomised trial. Lancet, 353 , 9– 13.DOI: 10.1016/s0140-6736(98)11181-9 8 MERIT-HF, Study Group. (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 353 , 2001– 2007.DOI: 10.1016/s0140-6736(99)04440-2 9 Nuttall SL, Langford NJ, Kendall MJ. (2000) Beta-blockers in heart failure. 1. Clinical Evidence. Journal of Clinical Pharmacy and Therapeutics, 25, 395– 398. 10 Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin MI. (1987) Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation, 75(Suppl. IV), 80– 92. 11 Cohn JN, Levine TB, Olivari MT. (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New England Journal of Medicine, 311 , 819– 823. 12 Kannel WB, Kannel C, Paffenbarger RSJ, Cupples LA. (1987) Heart rate and cardiovascular mortality: the Framingham Study. American Heart Journal, 113 , 1489– 1494. 13 Gillman MW, Kannel WB, Belanger A, Dagostino RB. (1993) Influence of heart rate on mortality among persons with hypertension: the Framingham Study. American Heart Journal, 125 , 1148– 1154. 14 Hjalmarson A, Gilpin E, Kjekshus J, et al. (1990) Influence of heart rate on mortality after acute myocardial infarction. American Journal of Cardiology, 1 , 547– 553. 15 Kjekshus J & Gullestad L. (1999) Heart rate as a therapeutic target in heart failure. European Heart Journal, 1(Suppl. H), H64– H69. 16 Moser DK, Stevenso WG, Woo MA, Stevenson LW. (1994) Timing of sudden death in patients with heart failure. Journal of the American College of Cardiology, 24 , 963– 967. 17 ISIS-2 Collaborative Group. (Second International Study of Infarct Survival). (1992) Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. European Heart Journal, 13 , 594– 598. 18 Brown BG, Zhao XQ, Sacco DE, Albers JJ. (1993) Lipid-lowering and plaque regression, new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation, 87 , 1781– 1791. 19 Kjekshus J, Blix AS, Grottum P, Aasen AO. (1981) Beneficial effects of vagal stimulation on the ischaemic myocardium during beta-receptor blockade. Scandinavian Journal of Clinical and Laboratory Investigation, 41 , 383– 389. 20 Kjekshus J. (1986) Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. American Journal of Cardiology, 43 , 43F– 49F. 21 Thomas JA & Marks BH. (1978) Plasma norepinephrine in congestive heart failure. American Journal of Cardiology, 41 , 233– 233. 22 St John Sutton M & Pfeffer MAML. (1997) Cardiovascular death and left ventricular remodelling two years after myocardial infarction. Baseline predictor and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) Trial. Circulation, 96 , 3294– 3299. 23 The Consensus Trial Group. (1987) Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine, 316 , 1429– 1435. 24 Julian DG, Camm AJ, Frangin G, et al. (1997) Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet, 349 , 667– 674.DOI: 10.1016/s0140-6736(96)09145-3 25 Kleiger RE, Miller JP, Bigger JT, Moss AJ. (1987) Decreased heart rate variability and its association with increased mortality after myocardial infarction. American Journal of Cardiology, 59 , 256– 262. 26 Casolo G, Balli E, Taddei T, Amumasi J, Gori C. (1989) Decreased spontaneous heart rate variability in congestive heart failure. American Journal of Cardiology, 64 , 1162– 1167. 27 Coumel P, Hermida JS, Wennerblom B, Leenhardt A, Maison-Blanche P, Cauchemez B. (1991) Heart rate variability in left ventricular hypertrophy and heart failure, and the effects of beta-blockade. European Heart Journal, 12 , 412– 422. 28 Niemelä MJ, Airakasinen KEJ, Huikuri H. (1994) Effect of beta-blockade on heart rate variability in patients with coronary artery disease. Journal of the American College of Cardiology, 23 , 1370– 1377. 29 Lechat P, Escolano S, Golmard JL, et al. (1997) Prognostic value of bisoprolol induced haemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation, 96 , 2197– 2205. 30 Lechat PP, Packer M, Chalon S. (1998) Clinical effects of beta adrenergic blockade in chronic heart failure: a meta analysis of double blind, placebo controlled randomised trials. Circulation, 98 , 1184– 1191. 31 Doughty RN, Whalley GA, Gamble G, Australia/New Zealand Heart Failure Research Collaborative Group. (1997) Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischaemic heart disease. Journal of the American College of Cardiology, 29 , 1060– 1066.DOI: 10.1016/s0735-1097(97)00012-0 32 Andersson B, Caidahl K, Waagstein F. (1994) Recovery from left ventricular asynergy in ischaemic cardiomyopathy following long-term beta blockade treatment. Cardiology, 85 , 14– 22. 33 Ng KS & Gibson DG. (1989) Impairment of diastolic function by shortened filling period in severe left ventricular disease. British Heart Journal, 62 , 246– 252. 34 Eichorn EJ & Bristow MR. (1996) Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation, 94 , 2285– 2296. 35 Metra M, Nodari S, D'Aloia A. (2000) A rationale for the use of beta-blockers as standard treatment for heart failure. American Heart Journal, 139 , 511– 521. 36 Podrid PJ, Fuchs T, Candinas R. (1990) Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation, 82 , 1103– 1113. 37 Yates YC, Beamish RE, Dhalla NS. (1981) Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. American Heart Journal, 102 , 210– 221. 38 Haft JI. (1974) Cardiovascular injury induced by sympathetic catecholamines. Progress in Cardiovascular Disease, 17 , 73– 86. 39 Katz A. (1988) Cellular mechanisms in congestive heart failure. American Journal of Cardiology, 62 , 3A– 8A. 40 Eichorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA. (1994) Effect of metoprolol on myocardial function and energetics in patients with non ischemic dilated cardiomyopathy: a randomiszed, double-blind, placebo controlled study. Journal of the American College of Cardiology, 24 , 1310– 1320. 41 Jewett SL, Eddy LJ, Hochstein P. (1999) Is the autoxidation of catecholamines involved in ischaemia-reperfusion injury? Free Radical Biology and Medicine, 6 , 185– 188. 42 McMurray J, Chopra MB, Abdullah I, Smith WE, Dargie HJ. (1993) Evidence of oxidative stress in chronic heart failure in humans. European Heart Journal, 14 , 1493– 1498. 43 Ferrari R, Agnoletti L, Comini L, et al. (1998) Oxidative stress during myocardial ischaemia and heart failure. European Heart Journal, 19(Suppl. B), B2– B11. 44 Lopez BL, Christopher TA, Tue T-L, Ruffolo R, Feuerstein GZ, Ma X-L. (1995) Carvedilol, new beta-adrenoceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology, 51 , 165– 173. 45 Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. (1996) Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. Journal of Cardiovascular Pharmacology, 27 , 532– 538. 46 Kukin ML, Kalman J, Charney RH, et al. (1999) Prospective, randomised comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation, 99 , 2645– 2651. Citing Literature Volume26, Issue1February 2001Pages 1-4 ReferencesRelatedInformation
Referência(s)